Are GLP-1 medications only for people with diabetes?

No. FDA-approved GLP-1 medications for weight loss — Wegovy and Zepbound — are indicated for adults with obesity or overweight with a weight-related health condition, regardless of whether diabetes is present. Some GLP-1 medications (Ozempic, Mounjaro) are FDA-approved specifically for diabetes but are sometimes prescribed off-label for weight management.

How quickly do GLP-1 medications work?

Most people begin to notice reduced appetite and some weight loss within the first four to eight weeks, though results continue to accumulate over months. Meaningful weight loss is typically assessed at the three- to six-month mark and beyond.

Will I regain weight if I stop taking a GLP-1?

Clinical evidence consistently shows that the majority of weight lost on GLP-1 medications is regained when treatment is discontinued, typically within one to two years. These medications are intended as long-term treatments, similar to how blood pressure or cholesterol medications are managed.

Can GLP-1 medications cause muscle loss?

Rapid weight loss from any source can include some loss of lean muscle mass. This is a clinically recognized concern with GLP-1 medications and is one reason resistance exercise is strongly encouraged during treatment — to preserve muscle while losing fat mass.

Are GLP-1 medications safe long-term?

Clinical trials of up to two years or more have shown GLP-1 medications to be well tolerated in most patients. Longer-term safety data continues to be collected. All medications carry risks, and ongoing monitoring with a provider is a standard component of GLP-1 treatment.

What Are GLP-1 Medications and How Do They Work for Weight Loss?

Q: Do I have to inject GLP-1 medications?

Most GLP-1 medications are administered as subcutaneous (under the skin) injections, typically once weekly. An oral semaglutide formulation specifically for weight loss received FDA approval in late 2026, providing an injection-free option for men who prefer a pill.

Over the past several years, a class of medications called GLP-1 receptor agonists has fundamentally changed the landscape of weight management. Originally developed to treat type 2 diabetes, these drugs produced weight loss results in clinical trials that far exceeded anything previously available — leading to FDA approvals specifically for obesity treatment and a wave of clinical and public interest that continues to grow. Understanding what GLP-1 medications are, how they work biologically, what the evidence shows, and who is an appropriate candidate is essential context for any man considering medical weight loss treatment.

What Is a GLP-1?

GLP-1 stands for glucagon-like peptide-1. It is a hormone naturally produced in the gut in response to eating. When food enters the small intestine, GLP-1 is released and performs several important functions: it stimulates the pancreas to release insulin (lowering blood sugar), it suppresses glucagon (a hormone that raises blood sugar), and it slows gastric emptying — the rate at which food leaves the stomach and moves into the intestine. This slowing of digestion is a key reason GLP-1 produces feelings of fullness and reduced appetite.

GLP-1 receptor agonists are synthetic drugs that mimic this hormone. They bind to the same receptors as natural GLP-1 but are engineered to last much longer in the body — hours to days rather than the minutes that natural GLP-1 persists before being broken down. This extended action is what makes them therapeutically useful for both blood sugar control and weight management.

How GLP-1 Medications Promote Weight Loss

Appetite Suppression

GLP-1 receptors are present not only in the pancreas and gut but in areas of the brain involved in hunger regulation — particularly the hypothalamus. When GLP-1 medications activate these receptors, they reduce appetite signals, making users feel less hungry between meals and less interested in food overall. Many patients report a significant reduction in food preoccupation and cravings.

Slowed Gastric Emptying

By slowing the rate at which food leaves the stomach, GLP-1 medications prolong the physical sensation of fullness after eating. This delays the return of hunger and reduces the overall amount of food consumed at subsequent meals.

Blood Sugar Regulation

GLP-1 medications improve insulin sensitivity and lower post-meal blood glucose spikes. This is their original mechanism for diabetes treatment but also contributes to weight loss indirectly, as better blood sugar regulation reduces the insulin-driven fat storage associated with chronically elevated glucose.

Reduced Reward Value of Food

Evidence suggests GLP-1 receptors in the brain's reward circuits may reduce the hedonic or pleasure-driven aspects of eating — meaning high-calorie foods become less appealing. This may help explain why many patients report not just eating less, but genuinely wanting less food.

The Main GLP-1 Medications Available

Semaglutide (Wegovy, Ozempic, Rybelsus)

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. It is available in three formulations: Ozempic (injectable, once weekly, approved for type 2 diabetes), Wegovy (injectable, once weekly, approved for weight loss), and Rybelsus (oral daily tablet, approved for type 2 diabetes). In December 2026, the FDA also approved an oral semaglutide formulation specifically for weight loss.

The STEP 1 trial — the pivotal phase 3 study for Wegovy — found that adults with obesity or overweight who took 2.4 mg of semaglutide weekly alongside lifestyle interventions lost an average of approximately 15% of their body weight over 68 weeks, compared to 2.4% in the placebo group.

Tirzepatide (Zepbound, Mounjaro)

Tirzepatide, developed by Eli Lilly, is a dual agonist — it activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP is another gut hormone that works alongside GLP-1 in regulating insulin and appetite. The dual mechanism appears to produce greater weight loss than GLP-1 agonism alone. Mounjaro is the brand name for tirzepatide approved for type 2 diabetes, and Zepbound is approved specifically for weight loss.

The SURMOUNT-1 trial found that adults taking the highest dose of tirzepatide (15 mg weekly) lost an average of 20.9% of their body weight over 72 weeks, compared to 3.1% in the placebo group.

Liraglutide (Saxenda, Victoza)

Liraglutide is an older GLP-1 receptor agonist administered as a daily injection. Saxenda is the weight loss formulation and Victoza is approved for type 2 diabetes. It is less potent for weight loss than semaglutide or tirzepatide but remains an option, particularly as generic liraglutide has become available at lower cost.

How Much Weight Can Men Lose on GLP-1 Medications?

Clinical trial data provides the most reliable benchmarks, though individual results vary based on starting weight, dosage, adherence, diet, and exercise.

In the STEP 1 trial for Wegovy, participants lost an average of approximately 15% of their body weight over 68 weeks. In the SURMOUNT-1 trial for Zepbound at the highest dose, average weight loss was approximately 20.9% over 72 weeks. Both trials required participants to follow a reduced-calorie diet and increased physical activity alongside medication, and those lifestyle components meaningfully amplified results.

A critical practical point: GLP-1 medications must be used long-term to maintain weight loss. When treatment is discontinued, appetite typically returns and the majority of lost weight is regained within one to two years. These are chronic treatments, not short-course interventions.

Who Are GLP-1 Medications For?

FDA-approved GLP-1 medications for weight loss are indicated for adults who meet one of the following criteria: a body mass index (BMI) of 30 or greater (classified as obesity), or a BMI of 27 or greater with at least one weight-related health condition such as type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnea, or cardiovascular disease.

GLP-1 medications are not appropriate for everyone. They are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2), due to a boxed warning for thyroid C-cell tumors observed in animal studies. They are also not appropriate for use during pregnancy. Men with a history of pancreatitis should discuss this with their provider, as GLP-1 medications have been associated with an increased risk in some cases. A full medical evaluation should precede any prescription for GLP-1 therapy.

Common Side Effects

The most common side effects of GLP-1 medications are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These effects are most pronounced when starting treatment or after dose increases and typically improve as the body adjusts over several weeks. In clinical trials, GI side effects caused roughly 5–10% of participants to discontinue treatment.

To minimize GI side effects, GLP-1 medications are initiated at a low starting dose and gradually titrated upward over weeks to months — a process called dose escalation. Eating smaller meals, avoiding high-fat or highly processed foods, and staying hydrated can also help reduce GI symptoms during the adjustment period.

GLP-1 Medications and Cardiovascular Health

Beyond weight loss, semaglutide has demonstrated cardiovascular benefits in clinical trials. The SELECT trial found that weekly semaglutide reduced the risk of major adverse cardiovascular events — including heart attack and stroke — by 20% in adults with obesity or overweight and established cardiovascular disease, even in those without type 2 diabetes. This led to FDA approval of Wegovy for cardiovascular risk reduction in that population.

Tirzepatide cardiovascular outcome data is still being collected in ongoing trials, though the metabolic improvements seen with the drug — including weight loss, blood sugar control, and reductions in blood pressure and lipids — suggest meaningful benefit.

When to Speak With a Provider

GLP-1 medications are prescription treatments that require clinical evaluation, regular monitoring, and long-term management. Any man interested in GLP-1 therapy should discuss it with a licensed healthcare provider — whether a primary care physician, endocrinologist, or obesity medicine specialist — who can assess eligibility, review medical history, recommend the most appropriate treatment, and provide ongoing monitoring and support.